Philadelphia Biotech Startup Context Therapeutics Names a New CFO, Effective Immediately Post author:Sam Post published:November 15, 2017 Post category:BioPharma The company is strengthening its team as it transitions to a clinical development stage company. Source: BioSpace You Might Also Like Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017 GE Healthcare to Shutter Maryland Plant, Nearly 200 Employees Affected February 6, 2017 Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017
Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017
Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017